New evidence
Rhodiola rosea outperformed placebo for mild depression in a meta-analysis of 1,049 patients — but the same review found no direct trials comparing antidepressants to placebo.
This is among the first meta-analyses to suggest rhodiola works for mild depression, but with only one pooled analysis behind it, the evidence is still too thin to rely on.
A systematic review of 1,049 people with milder depression found that rhodiola rosea reduced depressive symptoms more than placebo, with a moderate effect. However, the review also noted a striking gap: no randomized controlled trials have directly tested standard antidepressants against placebo in this population, and the overall quality of the available studies was low. So while rhodiola looks promising, this single meta-analysis isn't enough to change clinical practice — it's a signal, not a conclusion.
Where this fits in the evidence
This is among the first studies we've indexed on Rhodiola for Improved Depressive Symptoms — treat it as an early signal until more research accumulates.
The study
- Meta-Analysis
- n = 1,049
- 2025-02-27
- Neuropsychopharmacology reports
- PubMed: 40014460
- DOI: 10.1002/npr2.70008
- Full study breakdown →
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.